** Omnicell's OMCL.O shares down 7% at $42.81 Tues as medical software co seeks capital raise
** Fort Worth, Texas-based firm early Tues said offering privately $150 mln 5-yr convertible bonds (CBs)
** Co expects to use portion of net proceeds to pay for capped calls, remainder, along with cash, to repurchase up to $400 mln of its outstanding 0.25% CBs due 2025
** On Oct 29, shares soared 32% to close at $53.05 after co posted big adj Q3 EPS beat and hiked its FY 2024 earnings outlook
** With move on Tues, shares up 14% YTD for market value of ~$2 bln, per LSEG
** Of 9 analysts covering OMCL, 3 rate "buy", rest "hold"; median PT of $60 up from $44.50 a month ago
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper.thomsonreuters.com@reuters.net lance.tupper@tr.com 1-646-279-6380))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。